Florian Lordick Elected ESMO President 2029–2030

oncodaily - Professor Florian Lordick has been elected President of the European Society for Medical Oncology for the 2029–2030 term, marking a new leadership chapter for one of the world’s leading oncology […]

AI Summary: Florian Lordick will serve as ESMO president for 2029–2030, pledging to prioritise precision oncology, workforce development and stronger European collaboration. Colleagues praise his vision for translating research into practice and amplifying policy advocacy; expectations include initiatives to close care gaps and bolster international partnerships — because someone has to herd this many oncologists.

#healthcare #publichealth #governmentpolicy #oncology #cancerresearch #researchfunding #clinicaltrials #healthdisparities

3 hrs / oncodaily

4 hrs / oncodaily

4 hrs / oncodaily

4 days / oncodaily

4 days / esmo


Back to Top / Sun, June 7, 2026, 10:21 pm / permalink 24959 / 5 stories in 4 hrs /




Related Stories


AACR names 2026 Distinguished Service Award recipients / 7 wks

Introducing ISCO 2026 chairs and program highlights / 6 wks

Population lung screening lowers deaths in never‑smokers / 2 months

Studies neglect women's experiences in childbirth and breastfeeding research / 22 days

American Cancer Society launches pediatric and AYA cancer journal / 1 month

National study to use genetic testing to guide cancer survivor follow-up / 4 wks

Multiple cancers rising in young people; researchers probe possible causes / 5 wks

StackHealth RSS


You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Adolescent Health, Clinical Trials, Avian Influenza, Pfizer and look for the RSS link.





NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.